Literature DB >> 6110195

Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?

V W Henderson, G F Wooten.   

Abstract

The neuroleptic malignant syndrome (NMS) of extrapyramidal signs and hyperthermia is an uncommon complication of therapy with the major tranquilizers. Other manifestations are pallor, diaphoresis, blood pressure fluctuation, tachycardia, and tachypneic hypoventilation, which may necessitate respirator support. Death often occurs, but full recovery can result with prompt recognition and proper management. In a patient with Parkinson disease and a chronic psychiatric disorder treated with haloperidol, typical features of NMS appeared upon cessation of dopaminergic antiparkinsonian drugs. Manifestations of NMS are attributed to dopamine receptor blockade in the striatum, increasing thermogenesis, and in the hypothalamus, impairing heat dissipation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6110195     DOI: 10.1212/wnl.31.2.132

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  52 in total

1.  Fits and starts.

Authors:  S A Kausar; A Harvey; D Mukherjee
Journal:  Postgrad Med J       Date:  1998-11       Impact factor: 2.401

2.  Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease.

Authors:  Y Sato; T Asoh; N Metoki; K Satoh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-05       Impact factor: 10.154

3.  Missed neuroleptic malignant syndrome.

Authors:  D S Renwick; A Chandraker; P Bannister
Journal:  BMJ       Date:  1992-03-28

4.  Combined neuroleptic malignant syndrome and the central anticholinergic syndrome.

Authors:  D A Bennett
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-08       Impact factor: 10.154

Review 5.  Neuroleptic malignant syndrome: a neuroimmunologic hypothesis.

Authors:  Rebecca E Anglin; Patricia I Rosebush; Michael F Mazurek
Journal:  CMAJ       Date:  2010-08-09       Impact factor: 8.262

6.  Psychiatry-important advances in clinical medicine: neuroleptic malignant syndrome.

Authors:  C B Schaffer
Journal:  West J Med       Date:  1983-03

7.  The syndrome of Karl Ludwig Kahlbaum.

Authors:  M P Barnes; M Saunders; T J Walls; I Saunders; C A Kirk
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-09       Impact factor: 10.154

8.  A rapidly progressing lethal case of neuroleptic malignant syndrome.

Authors:  P Lenler-Petersen; B D Hansen; L Hasselstrøm
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

9.  Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome.

Authors:  W R Gibb; D N Griffith
Journal:  Postgrad Med J       Date:  1986-01       Impact factor: 2.401

10.  Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome.

Authors:  J Kornhuber; M Weller
Journal:  J Neural Transm Gen Sect       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.